# A Phase II Clinical Study of HRS-1893 in Non-obstructive Hypertrophic Cardiomyopathy

> **NCT06816251** · PHASE2 · RECRUITING · sponsor: **Shandong Suncadia Medicine Co., Ltd.** · enrollment: 84 (estimated)

## Conditions studied

- Non-obstructive Hypertrophic Cardiomyopathy

## Interventions

- **DRUG:** HRS-1893
- **DRUG:** HRS-1893 placebo

## Key facts

- **NCT ID:** NCT06816251
- **Lead sponsor:** Shandong Suncadia Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-25
- **Primary completion:** 2025-08
- **Final completion:** 2025-08
- **Target enrollment:** 84 (ESTIMATED)
- **Last updated:** 2025-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06816251

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06816251, "A Phase II Clinical Study of HRS-1893 in Non-obstructive Hypertrophic Cardiomyopathy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06816251. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*